Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
2008

Impact of Treatment on Large Intestine Histology in Chronic Hepatitis C Patients

Sample size: 24 publication Evidence: low

Author Information

Author(s): Pantazis Konstantinos D., Elefsiniotis Ioannis S., Papaioannou Dimitrios, Brokalaki Hero, Bonatsos Gerasimos, Mavrogiannis Christos

Primary Institution: University of Athens

Hypothesis

Does pegylated-interferon alpha plus ribavirin treatment affect the large intestine histology of chronic hepatitis C patients?

Conclusion

The study suggests that the treatment does not significantly affect the large intestine histology of treated patients.

Supporting Evidence

  • Patients exhibited no significant difference in bowel inflammatory infiltration compared to controls.
  • 25% of CHC patients showed architectural disorder and decreased mucus production.
  • 16.7% of CHC patients had Paneth cells present compared to none in controls.

Takeaway

Doctors wanted to see if a specific treatment for hepatitis C changed the way the intestines looked. They found it didn't really change much, even though some patients had tummy troubles.

Methodology

The study involved 24 treatment-naïve chronic hepatitis C patients who were treated with pegylated-interferon alpha and ribavirin for 24 weeks, with biopsies taken before and after treatment.

Limitations

The small sample size limits the generalizability of the findings.

Participant Demographics

14 males and 10 females, average age 37.04 years.

Digital Object Identifier (DOI)

10.1155/2008/637517

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication